What МИГ 200 Treats: Main Uses and Benefits

As a medicine applied across therapeutic domains involving distressing manifestations, МИГ 200 is used to address multiple symptoms related to physical discomfort, systemic imbalance, and inflammatory processes, helping with symptoms related to these key areas.

This medication is relevant for easing symptoms that interfere with daily comfort, such as tension-type headaches, dental pain, body aches (myalgia), menstrual cramps (dysmenorrhea), and fever. It is applied across conditions presenting with acute episodes and is considered relevant when supportive symptom management is appropriate.

“МИГ 200 is commonly used when short-term symptomatic assistance is needed to address acute discomfort and fever.”

---

Therapeutic Focus

МИГ 200 is relevant for easing symptoms across key therapeutic domains, including addressing symptoms related to mild to moderate pain; managing the discomfort, stiffness, and localized swelling associated with inflammatory states like minor sprains or strains; and is applied in addressing acute fever linked to seasonal illnesses. This supportive relief may help patients cope more steadily with symptom fluctuations and assists with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Pain, Inflammation, and Fever

Regulatory References

1. Ibuprofen: MedlinePlus Drug Information

Eligibility Map: Who can and cannot use МИГ 200 — Official Regulatory Information

The eligibility profile for МИГ 200 (Ibuprofen) is strictly defined by patient history, age, and pre-existing medical conditions, as stated in official government labeling.

---

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults and adolescents 12 years of age and older. Use in children 6 years and older (or ge 20 kg) is approved for specific dosage forms.
Populations for whom use is not recommended (if applicable): Children under 6 years of age. Use should be avoided in the first two trimesters of pregnancy unless medically necessary.
Populations for whom use is contraindicated: Patients with a history of allergic reactions to aspirin or other NSAIDs, active peptic ulcers/GI bleeding, severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure. Use is also prohibited right before or after CABG surgery and during pregnancy at 20 weeks gestation or later.

---

Eligibility Classifications (High-Level)
Age-related eligibility rules: The minimum approved age for the 200 mg tablet is typically 12 years old. Older adults require use with caution due to increased risk of serious gastrointestinal events.
Condition-specific eligibility rules: Use requires caution in patients with mild to moderate renal or hepatic impairment, certain cardiovascular risk factors (e.g., uncontrolled hypertension), or pre-existing GI diseases like Crohn's disease.
Pregnancy and lactation eligibility status: Use is Contraindicated after 20 weeks of pregnancy. Short-term use during lactation is generally considered acceptable.

---

Connection to the overall eligibility profile

Regulatory documents establish who can and cannot use this medicine by defining absolute contraindications—specific historical events (like an NSAID allergy) or severe, irreversible organ states that prohibit use. For other groups, such as older adults or those with mild chronic conditions, official labeling dictates conditional eligibility, requiring cautious use to manage documented, population-specific risk factors.

Interactions with other medicines and products

МИГ 200 (Ibuprofen) interacts with various medicinal products and substances, as officially documented in regulatory labeling. These interactions are classified into pharmacodynamic and pharmacokinetic patterns.

Co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is formally contraindicated due to a significantly increased risk of ulceration and bleeding. The medicine is also contraindicated for peri-operative use in the setting of Coronary Artery Bypass Graft (CABG) Surgery.

Pharmacodynamic interactions exist with Anticoagulants (Warfarin) and Oral Corticosteroids, both of which increase the documented risk of gastrointestinal bleeding. Ibuprofen may reduce the effectiveness of Antihypertensive Agents (e.g., Diuretics, ACE inhibitors), and the combination increases the risk of renal impairment, particularly in the elderly population.

Pharmacokinetic interactions occur with substances whose clearance is officially reduced by Ibuprofen. The medicine decreases the renal clearance of Lithium and Methotrexate, leading to increased plasma concentrations and potential toxicity. Furthermore, a timing-based separation is required for patients using low-dose, immediate-release Aspirin: Ibuprofen must be taken at least 8 hours before or 30 minutes after the Aspirin dose to minimize the documented attenuation of its antiplatelet effect.

Documented interactions with lifestyle substances include an increased risk of serious gastrointestinal bleeding when combined with Alcohol or Tobacco use.

The mechanism of МИГ 200 involves the pharmacodynamic actions of its ingredient, Ibuprofen, which modulates the inflammatory and thermoregulatory pathways via enzyme inhibition.

Core Mechanism: Enzyme Inhibition of Prostaglandin Synthesis

The drug functions by performing a non-selective, reversible inhibition of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2), which are responsible for converting arachidonic acid into chemical mediators called prostaglandins. This molecular interference modifies the early steps of the inflammatory cascade, leading to a reduction in PGE2 production at the site of injury.

Central Modulation of Temperature Signaling

The mechanistic action extends to the Central Nervous System, where Ibuprofen inhibits PGE2 synthesis within the hypothalamus. This targeted central interference opposes the PGE2-mediated elevation of the body's thermal set-point, thereby influencing the physiological processes of thermoregulation.

Pathway Specificity and Physiological Consequence

This enzyme-blocking mechanism affects two physiological consequences: it limits the PGE2-driven sensitization of peripheral nociceptors, and reduces the local fluid dynamics associated with inflammatory swelling. The mechanism is specific to the COX-prostaglandin pathway, meaning it modulates physiological responses that are primarily driven by these mediators.

The administration of МИГ 200 follows established protocols. This medicine, which contains Ibuprofen 200 mg, is designated for oral administration only, typically provided as a film-coated tablet or capsule.

The standard starting dose for adults is 200 mg, to be taken with a glass of water. If the initial dose is inadequate, a single dose may be increased to 400 mg. Dosing frequency is defined by an interval of every 4 to 6 hours, taken as necessary while symptoms persist. The maximum daily dose for non-prescription use is strictly limited to 1200 mg in a 24-hour period.

Regarding intake conditions, the tablet should be swallowed whole and may be consumed with food or milk to mitigate the potential for gastrointestinal discomfort. Furthermore, the duration of use for self-medication is typically limited to a maximum of 10 days for pain or 3 days for fever.

A critical procedural constraint across all uses is the adherence to the Lowest Effective Dose for the Shortest Duration (LED-SD) principle. For older adults, this principle necessitates particular caution to minimize both dose and duration. The 200 mg product is not intended for children under 12 years of age for self-medication and requires professional consultation to determine weight-appropriate dosing. If a dose is missed, the user should simply resume the schedule, maintaining the minimum 4 to 6-hour interval and avoiding double doses.

Research evidence / Overview of Studies for МИГ 200

This section outlines the research record for Ibuprofen, the active ingredient in МИГ 200, detailing the types of studies conducted and what outcomes were examined, without providing clinical advice or treatment recommendations. The findings align with the research record reviewed by regulatory and scientific bodies.

Evidence for Use in Acute Pain Relief

Research into the medicine's use for acute pain relies primarily on Randomized Controlled Trials (RCTs). The research was conducted using models of acute pain, which included conditions such as mild headache, dental discomfort, and pain associated with soft tissue strain. Primary outcomes monitored included the patient-reported change in pain intensity scores over short intervals and the time measured until a defined level of change in discomfort was reported. The volume of available trials suggests a substantial research base for short-term changes.

Evidence for Antipyretic Action (Fever Reduction)

The medicine was studied for its antipyretic (fever-reducing) action through numerous clinical trials. Research examined changes in body temperature in both adults and pediatric patients. The main outcomes monitored included the magnitude of the change in body temperature from the patient's baseline and the time measured until that change was observed. The evidence base for this use includes a large volume of trials in various age groups.

Research Gaps and Areas of Uncertainty

Scientific reviews highlight areas where research remains insufficient or where findings are heterogeneous. For acute indications (pain and fever), follow-up durations were limited, meaning most data reflect only the immediate response, and long-term outcomes are not fully established. Additionally, evidence for anti-inflammatory action is often extrapolated from studies using higher doses (typically 400 mg or more) and longer treatment periods, making the specific anti-inflammatory contribution of the low-dose, short-term МИГ 200 use case uncertain. Research cannot predict whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Ibuprofen: MedlinePlus Drug Information

Common questions about МИГ 200 (FAQ)

Q: How quickly does МИГ 200 usually start working?

Studies and official information indicate that the active ingredient in МИГ 200 generally begins to exert an effect relatively quickly after administration. Official literature suggests that an onset of action is often noted within 30 to 60 minutes. Pharmacokinetic data shows that the concentration of the medicine in the bloodstream typically reaches its highest level within one to two hours.

Q: How long does the effect of МИГ 200 typically last?

Regulatory documents indicate that the duration of action for the pain-relieving effect of the active ingredient is typically cited as four to six hours. This duration aligns with the interval commonly specified for use.

Q: What is the difference between МИГ 200 and other similar products?

МИГ 200 contains the active ingredient Ibuprofen, which is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) of the propionic acid derivative subclass. Regulatory texts note that NSAIDs are commonly categorized by their chemical structure and half-life, which influences the required frequency of use compared to some other products.

Q: Is МИГ 200 known to cause stomach upset?

Yes, official safety information often lists stomach upset, which includes terms like dyspepsia, nausea, or abdominal pain, among the common adverse reactions. Official guidance suggests use with food or milk as a measure to help reduce the potential for gastrointestinal discomfort.

Q: Is it okay to take МИГ 200 if I am also taking vitamins or supplements?

Official guidance on drug interactions primarily focuses on prescription medications. However, medical literature notes a potential concern with herbal supplements that possess blood-thinning effects, such as Ginger or Ginkgo biloba, as combining them with NSAIDs may increase the risk of bleeding. The patient should consult a health professional regarding their full list of concurrent products.

Q: What types of foods or drinks should be avoided when using МИГ 200?

Official safety warnings advise avoiding alcohol due to an increased risk of serious gastrointestinal bleeding when МИГ 200 is combined with it. The medication is generally recommended to be consumed with food or milk to help minimize potential stomach irritation.

Q: Does МИГ 200 interact with commonly used cold medicines?

Regulatory documents advise against combining МИГ 200 (Ibuprofen) with any other medicine containing an NSAID, which includes aspirin or naproxen, due to a significantly increased risk of side effects. This is a relevant consideration because many over-the-counter cold and flu medicines contain other analgesic ingredients.

Q: What does the research say about the effectiveness of МИГ 200?

Clinical trials and authoritative regulatory reviews confirm that the active ingredient in МИГ 200 has demonstrated effectiveness for the short-term symptomatic treatment of mild to moderate pain, inflammation, and fever. Evidence indicates that its use for these symptomatic indications is supported by scientific study.

Q: Is МИГ 200 a prescription medicine or can I buy it over the counter?

The 200 mg formulation of the active ingredient is typically classified as an Over-The-Counter (OTC) medicine in many regions. This status allows individuals to purchase it without a prescription for managing self-limited conditions such as minor pain or fever.

Q: Is МИГ 200 the same type of medicine as [Aspirin/Tylenol/other common comparator]?

МИГ 200 is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) due to its core action on the body's inflammatory process. While it belongs to the same class as Aspirin, it is in a distinct pharmacological class from Acetaminophen (often known as Tylenol), which does not share the same anti-inflammatory properties.

Q: Can МИГ 200 make you feel drowsy or sleepy?

Official regulatory documents list dizziness and headache as common adverse reactions. While less frequent, some central nervous system (CNS) effects, including drowsiness or somnolence, have been mentioned in official reviews. Official labeling suggests caution regarding operating machinery.

Q: Are there any common but mild side effects of МИГ 200?

Regulatory documentation classifies side effects that affect a large number of users (typically 1% to 10%) as 'common.' These often involve mild digestive issues, such as nausea or dyspepsia, and central nervous system effects, such as headache or dizziness.

Q: Does taking МИГ 200 affect blood pressure?

Official safety information indicates that medications in this class may affect blood pressure. NSAIDs, including the active ingredient in МИГ 200, have been noted to potentially increase blood pressure or reduce the effectiveness of blood pressure-lowering medications.

Q: Can МИГ 200 interact with herbal remedies?

Yes, medical and regulatory guidance often highlights potential risks. Specifically, combining Ibuprofen with herbal supplements that have blood-thinning properties (like anti-platelet effects) is noted as potentially increasing the risk of bleeding.

Q: Is there any research that looked at long-term use of МИГ 200?

Authoritative reviews have examined long-term use of the active ingredient, particularly at higher prescription doses. Regulatory bodies state that chronic, high-dose use is associated with a small, increased risk of cardiovascular events, but this risk is not stated in regulatory documents for the low-dose formulation used on a short-term basis.

Q: Is it normal to feel a tingling sensation after taking МИГ 200?

A tingling sensation (paresthesia) is not listed among the common side effects of the medicine. However, the official adverse event reporting systems do include various neurological symptoms, such as paresthesia, in the category of less frequently reported effects.

Q: Does МИГ 200 carry a risk of allergic reaction?

Yes, the official label includes a clear Allergy Alert, noting that the active ingredient may cause a severe allergic reaction. This risk is highest in people who have had a prior allergic reaction to aspirin or other NSAIDs, and hypersensitivity reactions are a formal contraindication.

Q: Is there any information on how МИГ 200 affects the ability to drive or operate machinery?

Official labeling advises that since side effects like dizziness or drowsiness may occur, Official labeling suggests that users be aware of their reaction to the drug before driving or operating machinery. If these effects are experienced, individuals are advised to avoid these activities.

Q: Does МИГ 200 contain caffeine or other stimulants?

The standard 200 mg formulation of МИГ 200 is officially labeled as a single-ingredient product, containing only Ibuprofen as the active component. Regulatory labeling does not list caffeine or other stimulants as ingredients in this formulation.

Q: What does the term 'contraindication' mean for МИГ 200?

In regulatory terms, a contraindication is a condition or circumstance that means the medicine must not be used. For МИГ 200, this is because the risk of serious harm, such as a severe allergic reaction, gastrointestinal bleeding, or severe organ failure, is considered too high for that specific patient or condition.

Q: What are the differences in how МИГ 200 is used compared to other medicines in its class?

Regulatory information specifically defines the use of МИГ 200 for short-term, acute pain and fever. Differences in use for other medicines in the NSAID class are often based on their approved duration of use (acute vs. chronic) and their pharmacological half-life, which affects how often the medicine is administered.

Q: Has МИГ 200 been involved in any high-profile clinical studies?

The active ingredient Ibuprofen has been the subject of numerous large Randomized Controlled Trials (RCTs) and extensive regulatory reviews globally. These high-profile studies have provided the foundation for its approved uses, established its dosage ceilings for safety, and continuously examined its long-term risk profile.

Storage and Disposal Requirements

Official labeling for МИГ 200 (Ibuprofen 200 mg) mandates strict storage and disposal procedures to ensure product stability and prevent harm.

Item	Official Regulatory Requirement
Storage Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid excessive heat above 40 C (104 F).
Protection Requirements	Keep the container tightly closed and protect the tablets from moisture. The product should be used by the expiration date.
Child Safety Storage	The medicine must be kept out of the sight and reach of children at all times.
Disposal Instructions	The preferred disposal method is a drug take-back program. The product must not be flushed down a toilet or sink.

Disposal in household trash is permissible only if the tablets are first mixed with an undesirable substance, placed in a sealed bag, and personal information is obscured on the container.